Answers are grounded in this paper and cite their sources.
In an effort to develop alternatives to hydroxamate-based matrix metalloproteinase inhibitors (MPIs), we have utilized the drug discovery program LUDI enhanced with the structural coordinates of a bioinorganic model complex. This method has yielded the first pyrone-based MPIs. The inhibitors demonstrate nanomolar potency against MMP-3 and are selective for MMP-3 over MMP-2 and MMP-1. We postulate that the potency and unusual selectivity profile of these MPI is attributable to the pyrone chelating group.
No takes yet. Share an insight, caveat, or question.
Puerta et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: